Brain MRI Cortical Diffusion Analysis for Dementia Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing dementia, particularly Alzheimer's disease and other cognitive disorders, are subjective, invasive, and lack accuracy, making it difficult to differentiate between types of dementia and provide effective clinical intervention.
Innovation Solution
A non-invasive method using MRI-based cortical diffusion data, including measurements such as AngleR, Axial Diffusivity, and Perpendicular Diffusivity, is applied to assess microstructural changes in specific brain regions to differentiate between different types of dementia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard structural brain MRI with visual assessment is used, then the method is non-invasive and easy to perform, but the diagnostic accuracy is low due to subjective assessment
Solution Approach 1:
The patent transforms standard structural MRI into a quantitative diagnostic tool by changing the measurement parameters from visual assessment to automated volumetric analysis. Specific parameters including hippocampal volume, ventricular volume, and cortical thickness are extracted and compared against normative databases to generate objective diagnostic criteria, thereby resolving the contradiction between maintaining simplicity and improving diagnostic accuracy.
Solution Approach 2:
The patent replaces the subjective mechanical/visual assessment process with an automated computational system. The imaging method transitions from human visual inspection to computer-based quantitative analysis using standardized protocols and automated measurement algorithms, eliminating subjectivity while maintaining the non-invasive nature of MRI.
2Reliability
If cognitive tests with fixed score boundaries are used, then the assessment is standardized, but the boundaries are changeable and open to interpretation reducing reliability
Solution Approach 1:
The patent transitions from qualitative cognitive test scores to quantitative neuroanatomical measurements. By measuring objective structural parameters such as hippocampal volume and cortical thickness, and comparing these against established normative ranges, the system provides reliable diagnostic criteria that are not subject to interpretation changes, thereby improving reliability while using standardized imaging protocols.
3Measurement precision
If invasive methods for CSF or blood biomarker detection are used, then accurate biochemical markers can be obtained, but the methods carry risk to patients preventing repetition
Solution Approach 1:
The patent replaces invasive biochemical sampling with non-invasive imaging-based biomarker detection. Quantitative MRI measurements of neuroanatomical structures serve as surrogate biomarkers for Alzheimer's disease and other cognitive disorders, providing accurate diagnostic information without exposing patients to procedural risks, thereby enabling safe repeated assessments over time.
4Difficulty of detecting and measuring
If standard volumetric MRI is used, then non-invasive imaging is achieved, but the ability to detect microscopic neuropathological changes is insufficient
Solution Approach 1:
The patent enhances standard volumetric MRI by implementing specialized acquisition protocols and advanced post-processing techniques that extract microstructural information from macroscopic imaging data. Through quantitative analysis of diffusion properties, cortical thickness, and volumetric measurements, the system detects subtle microstructural changes associated with early neuropathology, bridging the gap between non-invasive imaging capabilities and microscopic disease detection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a high predictive accuracy (>90%) for distinguishing between Alzheimer's disease and cerebrovascular dementia and can indicate the presence and severity of cognitive disorders, allowing for targeted treatment strategies.
Implementation Method 1
cortical diffusion data is magnetic resonance (MR) relaxometry data. The diffusion data may be measured directly from an MRI scan of the subject's brain
Implementation Method 2
magnetic resonance (MR) relaxometry data
Data Source
Figure 1A
Figure 1B~1C
Figure 2
AI summary
The present disclosure relates generally to medical imaging and, more particularly, it relates to methods and systems for performing processing of magnetic resonance (MR) imaging of the brain which may be useful in the diagnosis of cognitive disorders. More specifically, the invention includes methods for processing cortical diffusion data from a region of a subject's brain,comprisingdetermining values for the Axial Columnar Refraction (ACR)using values for AngleR and Axial Diffusivity.